February 24, 2022


Study authors Anne Geller, left, and Jun Yan
Pancreatic cancer is one of the deadliest cancers, with a five-year survival rate of just 10% for patients diagnosed with pancreatic ductal adenocarcinoma (PDAC), the most common type. Further, one promising area of cancer treatment, immunotherapy, has not provided benefit for pancreatic cancer patients. University of Louisville researchers recently have shown that beta-glucan, a natural...
Read More